EFFICACY OF GRANULOCYTE COLONY-STIMULATING FACTOR AND ENTEROSORPTION IN MELPHALAN-INDUCED BONE MARROW SUPPRESSION IN GUERIN CARCINOMA GRAFTED RATS
Background. Side effects of antineoplastic agents (especially leukopenia and neutropenia) could be the main limiting factors for efficient treatment.
Objective. The research is aimed at the study of myeloprotective capability of biosimilars of granulocyte colony stimulating factor (G-CSF) and granular carbon oral adsorbent C2 in melphalan-induced bone marrow suppression in Guerin carcinoma-grafted rats.
Methods. Melphalan at the dose of 5.5 mg/kg was used to promote bone marrow suppression in the Guerin carcinoma grafted rats. To fight myelosuppression, we used filgrastim and its analogue, designed and produced by IEPOR, a recombinant granulocyte colony-stimulating factor (r-GCSF). Carbon granulated enterosorbent C2 was used for enteral sorption therapy (bulk density γ=0.18 g/cm3, diameter of granules 0.15-0.25 mm, BET pore surface – 2162 m2/g). All rats were sacrificed on the 17th day after carcinoma cells inoculation or on the 8th day after Melphalan injection.
Results. Alkylating cytostatic agent caused severe leukopenia (by 95.7%), neutropenia (by 73.9%), and thrombocytopenia (by 84.9%) in the experimental rats. Mortality rate was 57%. Filgrastim and enterosorption with carbon oral adsorbent C2 increased the studied indices, but the most prominent results were observed when combination of both factors was used. Studied means did not affect the anti-tumor efficacy of Melphalan alone and in combination.
Conclusions. Our results are perspective for further investigation of the efficacy of the combination of carbon oral adsorbents and hematopoietic cytokines in cases of ameliorate anti-cancer chemotherapy side effects, and its implementation into clinics.
Xing C, Liang B, Wu J, Yang Q, Hu G, Yan Y, et al. Prognostic significance of leukopenia during the induction phase in adult B cell acute lymphoblastic leukemia. Cancer Manag Res. 2018;10:625-35. doi: 10.2147/CMAR.S158359
Al-Ansari S, Zecha JAEM, Barasch A, de Lange J, Rozema FR, Raber-Durlacher JE. Oral Mucositis Induced By Anticancer Therapies. Curr Oral Heal Reports. 2015 Dec 19;2(4):202-11. doi: 10.1007/s40496-015-0069-4
Turgeman O, Medical R, Blumenfeld Z, Medical R. Minimizing the doxorubicin-Induced gonadotoxicity by sphingosine-1-phosphate analogue FTY720 Minimizing the doxorubicin-Induced gonadotoxicity by. Am J Clin Exp Obs Gynecol. 2015;2(1):24-33.
Wang Y, Probin V, Zhou D. Cancer therapy-induced residual bone marrow injury-Mechanisms of induction and implication for therapy. Curr Cancer Ther Rev. 2006 Aug 1;2(3):271-9. doi: 10.2174/157339406777934717
Gaducci A, Gargini A, Palla E, Fanucchi A, Genazzani AR. Neutropenic Enterocolitis in an Advanced Epithelial Ovarian Cancer Patient Treated with Paclitaxel/Platinum-based Chemotherapy: A Case Report and Review of the Literature. Anticancer Res. 2005;(25):2509-14. Available from: https://pdfs.semanticscholar.org/e16b/eea03afd2a93686821eff80a60696893301f.pdf
Lalami Y, Klastersky J. Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data. Crit Rev Oncol Hematol. 2017;120(June):163-79. doi: 10.1016/j.critrevonc.2017.11.005
Denduluri N, Patt DA, Wang Y, Bhor M, Li X, Favret AM, et al. Dose delays, dose reductions, and relative dose intensity in patients with cancer who received adjuvant or neoadjuvant chemotherapy in community oncology practices. JNCCN J Natl Compr Cancer Netw. 2015 Nov;13(11):1383-93. doi: 10.6004/jnccn.2015.0166
Santolaya ME, Alvarez AM, Avilés CL, Becker A, Mosso C, O'Ryan M, et al. Admission clinical and laboratory factors associated with death in children with cancer during a febrile neutropenic episode. Pediatr Infect Dis J. 2007 Sep;26(9):794-8. doi: 10.1097/INF.0b013e318124aa44
Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S, Gianni L, et al. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ. 2005 Jan 29;330(7485):217. doi: 10.1136/bmj.38314.622095.8F
Barnes G, Pathak A, Schwartzberg L. Pharmacoeconomics of Granulocyte Colony-Stimulating Factor: A Critical Review. Adv Ther. 2014 Jul 3;31(7):683-95. doi: 10.1007/s12325-014-0133-9
Xie J, Cao J, Wang J, Zhang B, Zeng X, Zheng H, et al. Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study. Breast Cancer Res Treat. 2018 Apr 11;168(2):389-99. Available from: http://link.springer.com/10.1007/s10549-017-4609-6
Nikolaev VG. Sorption Therapy with the Use of Activated Carbons: Effects on Regeneration of Organs and Tissues. In: Hemoperfusion, Plasmaperfusion and Other Clinical Uses of General, Bio_specific, Immuno and Leucocyte Adsorbents. WSPC; 2017. p. 221-43. doi: 10.1142/9789814749084_0007
Nikolaev VG, Sakhno LA, Snezhkova EA, Sarnatskaya VV, Yushko LA. Carbon adsorbents in oncology: Achievements and perspectives. Exp Oncol. 2011;33(1):2-8.
Nikolaev VG, Samsonov VA. Analysis of medical use of carbon adsorbents in China and additional possibilities in this field achieved in Ukraine. Artif Cells, Nanomedicine, Biotechnol. 2014;42(1):1-5. doi: 10.3109/21691401.2013.856017
Muravskaya G V., Nikolaev VG, Sergeev VP, Krutilina NI, Bonatskaya L V., Klevtsov VN, et al. Enterosorption in Oncotherapy. Artif Cells, Blood Substitutes, Biotechnol. 1991;19(1):167-74. doi: 10.3109/10731199109117823
Shevchuk OO, Posokhova KA, Todor IN, Lukianova NY, Nikolaev VG, Chekhun VF. Prevention of myelosuppression by combined treatment with enterosorbent and granulocyte colony-stimulating factor. Exp Oncol. 2015;37(2):135-8. doi: 10.31768/2312-8852.2015.37(2):135-138
Shevchuk OO, Posokhova KA, Sidorenko AS, Bardakhivska KI, Maslenny VM, Yushko LA, et al. The influence of enterosorption on some haematological and biochemical indices of the normal rats after single injection of melphalan. Exp Oncol. 2014;36(2):94-100.
Liu W, Zhang C-C, Li K. Prognostic value of chemotherapy-induced leukopenia in small-cell lung cancer. Vol. 10, Cancer Biology & Medicine. Chinese Anti-Cancer Association; 2013. p. 92-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23882424
Held TK, Gundert-Remy U. Pharmacodynamic Effects of Haematopoietic Cytokines: The View of a Clinical Oncologist. Basic Clin Pharmacol Toxicol. 2010 Mar 1;106(3):210-4. doi: 10.1111/j.1742-7843.2009.00514.x
American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol. 1994 Nov;12(11):2471-508. doi: 10.1200/JCO.1918.104.22.1681
Lyman GH, Allcott K, Garcia J, Stryker S, Li Y, Reiner MT, et al. The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review. Support Care Cancer. 2017 Aug 8;25(8):2619-29. doi: 10.1007/s00520-017-3703-y
Vial T, Descotes J. Clinical Toxicity of Cytokines Used as Haemopoietic Growth Factors. Drug Saf. 1995 Dec;13(6):371-406. doi: 10.2165/00002018-199513060-00006
Gavioli E, Abrams M. Prevention of granulocyte-colony stimulating factor (G-CSF) induced bone pain using double histamine blockade. Support Care Cancer. 2017 Mar 5;25(3):817-22. doi: 10.1007/s00520-016-3465-y
Khoury H, Adkins D, Brown R, Vij R, Westervelt P, Trinkaus K, et al. Adverse side-effects associated with G-CSF in patients with chronic myeloid leukemia undergoing allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2000 Jun 5;25(11):1197-201. doi: 10.1038/sj.bmt.1702423
Mehta HM, Malandra M, Corey SJ. G-CSF and GM-CSF in Neutropenia. J Immunol. 2015 Aug 15;195(4):1341-9.
Heslet L, Bay C, Nepper-Christensen S. Acute radiation syndrome (ARS) - treatment of the reduced host defense. Int J Gen Med. 2012;5:105-15. doi: 10.2147/IJGM.S22177
Sarnatskaya VV, Sakhno L, Paziuk LM, Yushko LA, Rodionova NK, Maslenniy VN, et al. Highly activated carbon enterosorbent mediates the suppression of paraneoplastic syndrome associated with Lewis lung carcinoma in mice. Exp Oncol. 2018 Mar;40(1):33-41. doi: 10.31768/2312-8852.2018.40(1):33-41
Mikhalovsky SV, Sandeman SR, Howell CA, Phillips GJ, Nikolaev VG. Biomedical Applications of Carbon Adsorbents. In: Novel Carbon Adsorbents. Elsevier; 2012. p. 639-69. doi: 10.1016/B978-0-08-097744-7.00021-1
Ponomariova OV, Pivniuk VM, Nosko MM, Sakhno LO, Dekhtiar TV, Nikolaev VG, et al. Prophylaxis with carbon enterosorbent of acute and delayed emetogenic toxicity of chemotherapy treatment in oncologic patients. Onkologia. 2008;10(3):370-3 [in Ukrainian]. Available from: http://dspace.nbuv.gov.ua/handle/123456789/11944
Sakhno LA, Yurchenko OV, Maslenniy VN, Bardakhivskaya KI, Nikolaeva VV, Ivanyuk AA, et al. Enterosorption as a method to decrease the systemic toxicity of cisplatin. Exp Oncol. 2013;35(1):45-52. Available from: http://dspace.nbuv.gov.ua/handle/123456789/13911
Authors who sent their manuscript to International Journal of Medicine and Medical Research agree to the following terms:
1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License CC-BY-NC that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
2. Authors able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).